OptimOva® is a patented method developed at Oslo University Hospital. The blood test personalises hormone dosing by fine-tuning the routine dosing method and adjusting the prescribed dose to the patient’s needs.

OptimOva® is a diagnostic decision-tool for the clinician which allows accurate patient-specific hormone dosage by a blood biomarker-based technology.

OptimOva® allows the hormone dosage to be fine-tuned enabling the optimal number of egg cells (8–12) to be obtained on the day of egg cell retrieval. This reduces the risk of treatment cancellation due to too low or too high hormone response. The result of the test can be obtained within 4 hours of sample collection.

If you would like to find out more about OptimOva®, please send us an email at info@ivffit.com or Follow us on Linkedin https://www.linkedin.com/company/ivffit/

Members of: